Compare IMKTA & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMKTA | NTLA |
|---|---|---|
| Founded | 1963 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1994 | 2016 |
| Metric | IMKTA | NTLA |
|---|---|---|
| Price | $89.39 | $16.68 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 23 |
| Target Price | N/A | ★ $20.02 |
| AVG Volume (30 Days) | 133.1K | ★ 6.4M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,334,032,609.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $62.75 |
| P/E Ratio | $15.91 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $59.27 | $7.95 |
| 52 Week High | $95.62 | $28.24 |
| Indicator | IMKTA | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 50.23 | 64.05 |
| Support Level | $86.11 | $11.73 |
| Resistance Level | $89.76 | $26.99 |
| Average True Range (ATR) | 2.34 | 1.18 |
| MACD | -0.18 | 0.28 |
| Stochastic Oscillator | 39.47 | 87.18 |
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.